abemaciclib + exemestane + everolimus

This is a **combination therapy** consisting of three small molecule agents: abemaciclib (a selective oral cyclin-dependent kinase 4/6 inhibitor), exemestane (an irreversible steroidal aromatase inhibitor), and everolimus (an mTOR inhibitor). It is being investigated for the treatment of patients with **hormone receptor-positive, HER2-negative metastatic breast cancer**. - **Abemaciclib** blocks CDK4/6 activity, leading to cell cycle arrest in tumor cells. - **Exemestane** reduces estrogen levels by blocking aromatase, suppressing hormone-driven tumor growth. - **Everolimus** inhibits mTOR, a key regulator of cell growth, proliferation, and survival, further restricting cancer progression. This combination targets cell proliferation via CDK4/6 inhibition, hormone signaling through aromatase inhibition, and cell growth/survival via mTOR blockade.

Other names

abemaciclib + exemestane + everolimus